Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1451743rdf:typepubmed:Citationlld:pubmed
pubmed-article:1451743lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0694598lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0360055lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C2917412lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C1519355lld:lifeskim
pubmed-article:1451743lifeskim:mentionsumls-concept:C0815279lld:lifeskim
pubmed-article:1451743pubmed:issue1lld:pubmed
pubmed-article:1451743pubmed:dateCreated1993-1-7lld:pubmed
pubmed-article:1451743pubmed:abstractTextThe effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 microM), exacerbated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist, Y-25130 (0.1-100 microM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 microM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 microM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 microM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.lld:pubmed
pubmed-article:1451743pubmed:languageenglld:pubmed
pubmed-article:1451743pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:citationSubsetIMlld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1451743pubmed:statusMEDLINElld:pubmed
pubmed-article:1451743pubmed:monthNovlld:pubmed
pubmed-article:1451743pubmed:issn0014-2999lld:pubmed
pubmed-article:1451743pubmed:authorpubmed-author:WatanabeSSlld:pubmed
pubmed-article:1451743pubmed:authorpubmed-author:KagamiYYlld:pubmed
pubmed-article:1451743pubmed:authorpubmed-author:ShigenobuSSlld:pubmed
pubmed-article:1451743pubmed:issnTypePrintlld:pubmed
pubmed-article:1451743pubmed:day24lld:pubmed
pubmed-article:1451743pubmed:volume224lld:pubmed
pubmed-article:1451743pubmed:ownerNLMlld:pubmed
pubmed-article:1451743pubmed:authorsCompleteYlld:pubmed
pubmed-article:1451743pubmed:pagination51-6lld:pubmed
pubmed-article:1451743pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:meshHeadingpubmed-meshheading:1451743-...lld:pubmed
pubmed-article:1451743pubmed:year1992lld:pubmed
pubmed-article:1451743pubmed:articleTitleNeuroprotective effect of 5-HT3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices.lld:pubmed
pubmed-article:1451743pubmed:affiliationDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.lld:pubmed
pubmed-article:1451743pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1451743pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1451743lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1451743lld:pubmed